Huang et al. (2022) revealed that in the tumor tissues of recurrent gastric cancer (GC) patients undergoing treatment with capecitabine and cisplatin, there was a decrease in Sp1 SUMOylation levels, an increase in Sp1 expression, and enhanced binding of Sp1 to the SNHG17 promoter. Here, SP1 is linked to gastric cancer.